The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice finds there today - Thank you
I still struggle to understand why this company continues to fly completely under the radar, although I am pretty sure that will change over the next 6 months!
Hey, that's great!
20th June I asked: "PS If anyone knows a company breaking new ground in the arthritis field I will be very interested to know!"
Now this. I asked because for years I worked in a non-medical capacity in hospitals and saw just so much long term damage and debilitation due to asthma, arthritis, and in children eczema that I used to think if they just could take the research money going into cancer for 1 year and put it into those three what a gigantic difference it could make. You could put it that preventing death is one thing, but saving life is another. Also so vital.
Thanks Trek.
Incidentally all 3 may be autoimmune diseases - our area. Wow.
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, is pleased to note the publication of research, supported by its ImmunoINSIGHTS team, in Arthritis Research & Therapy1, entitled 'Profiling IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicentre national cohort of early arthritis in Germany'. The published paper demonstrates the potential to improve early Rheumatoid arthritis (RA) detection using autoantibodies, which, when combined with appropriate therapy/treatment could substantially improve outcomes for patients.
ImmunoINSIGHTS, Oncimmune's autoantibody profiling technology and service business, continues to work in partnership with therapy developers to generate, actionable, value-adding insights for their drug development programmes.
Rheumatoid arthritis is characterised by an inflammation with subsequent progressive destruction of joints. Approximately one-third of people stop work because of RA within 2 years of its onset, increasing thereafter. However, the currently widely available tests for rheumatoid factor and anti-citrullinated peptide antibodies (ACPA) can only be detected in 70-80% of RA patients, and hence the disease is commonly under-diagnosed.
The aim of the research, led by Oncimmune's Dr. Petra Buddle and Dr Hans-Dieter Zucht, was to assess the diagnostic potential of IgG antibodies to citrullinated and corresponding native autoantigens in early arthritis. The multicentre study involved a total of 411 patients, enrolled at baseline, and a serum sample drawn for autoantibody profiling. 309 (75.2%) patients were eventually classified as having RA. For further analysis, the cohort was randomly split into a test cohort (n?=?329) and a validation cohort (n?=?82). Patients eventually classified as having RA during follow-up were compared to patients who were not classified as having RA during follow-up.
The paper concludes that the autoantibody, cTRA2B-IgG, has the potential to improve diagnosis of early stage rheumatoid arthritis, which to date has been challenging due to current availability of diagnostics in the therapeutic area.
Dr Adam M Hill, CEO of Oncimmune said: "Oncimmune's ImmunoINSIGHTS team have once again contributed world class science to our collective understanding of a disabling disease, moving the needle in a hard to treat condition. RA is insidious in onset, often resulting in a diagnosis later in the evolution of the disease; clearly, candidate biomarkers able to identify the disease earlier in the majority of sufferers presents a near term opportunity to dramatically improve outcomes. Whilst we remain steadfast in our commitment to cancer patients - supporting the clinical understanding of autoimmune disease biomarkers better enables us to predict side effects in cancer patients treated with immune modulating drugs - the potential to work with biopharma in autoimmune disease is also a possibilit
Oncimmune Holdings PLC (LON:ONC) has noted that researchers driving innovation at the cancer diagnostic group have contributed "world-class science” to the field of rheumatoid arthritis (RA) and it’s early detection.
That’s the opinion of Oncimmune’s chief executive, Dr Adam Hill, whose ImmunoINSIGHTS team was integral to a paper published in the journal ‘Arthritis Research & Therapy’.
Led by Oncimmune's Dr Petra Buddle and Dr Hans-Dieter Zucht, a study was set up to assess the diagnostic potential of IgG antibodies in early RA. It did so by assessing 411 patients enrolled in Germany.
The scientists concluded that the autoantibody, cTRA2B-IgG, had the potential to improve diagnosis of early-stage rheumatoid arthritis.
“RA is insidious in onset, often resulting in a diagnosis later in the evolution of the disease; clearly, candidate biomarkers able to identify the disease earlier in the majority of sufferers presents a near term opportunity to dramatically improve outcomes,” said CEO Hill in a statement.
“Whilst we remain steadfast in our commitment to cancer patients - supporting the clinical understanding of autoimmune disease biomarkers better enables us to predict side effects in cancer patients treated with immune modulating drugs - the potential to work with biopharma in autoimmune disease is also a possibility," he added.
More details on the paper, 'Profiling IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicentre national cohort of early arthritis in Germany', can be accessed by clicking this link.
https://www.proactiveinvestors.co.uk/companies/news/923685/oncimmune-team-contributes--world-class-science--to-rheumatoid-arthritis-research-923685.html
https://www.investegate.co.uk/oncimmune-hldngs-plc--onc-/rns/paper-highlights-potential-of-immunoinsights-in-ra/202007080700053039S/
This co is a sleeping giant!
Trek